Citius Oncology, Inc. CTOR Working Capital
Working Capital at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:WorkingCapital.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s working capital?
- Citius Oncology, Inc. (CTOR) reported working capital of $29.4M in Q1 2026.
- How has Citius Oncology, Inc.'s working capital changed year-over-year?
- Citius Oncology, Inc.'s working capital decreased by 7.3% year-over-year, from $31.7M to $29.4M.
- What does working capital mean?
- The difference between current assets and current liabilities, representing the liquidity available for day-to-day operations. For a pharmaceutical company, this indicates the ability to fund ongoing clinical trials and research activities without requiring immediate external financing. A healthy balance is vital for maintaining operational continuity and meeting short-term obligations.